共 159 条
[1]
Čelakovská J(2021)Analysis of results of specific IgE in 100 atopic dermatitis patients with the use of multiplex examination ALEX2-allergy explorer Int J Mol Sci 22 5286-96
[2]
Bukač J(2020)Dupilumab: basic aspects and applications to allergic diseases Allergol Int 69 187-43
[3]
Cermákova E(2017)Therapeutic pipeline for atopic dermatitis: end of the drought? J Allergy Clin Immunol 140 633-9
[4]
Matsunaga K(2014)Dupilumab treatment in adults with moderate-to-severe atopic dermatitis N Engl J Med 371 130-48
[5]
Katoh N(2016)Two phase 3 trials of dupilumab versus placebo in atopic dermatitis N Engl J Med 375 2335-52
[6]
Fujieda S(2016)Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial Lancet 387 40-303
[7]
Izuhara K(2017)Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial Lancet 389 2287-58
[8]
Oishi K(2017)Two phase 3 trials of dupilumab versus placebo in atopic dermatitis N Engl J Med 376 1090-225
[9]
Paller AS(2021)Efficacy and safety of dupilumab for moderate-to-severe atopic dermatitis: a systematic review for the EAACI biologicals guidelines Allergy 76 45-10
[10]
Kabashima K(2016)Evaluation by citation: trends in publication behavior, evaluation criteria, and the strive for high impact publications Sci Eng Ethics 22 199-66